Fedratinib:一种新获批用于治疗骨髓增殖性肿瘤相关骨髓纤维化的药物
骨髓增殖性肿瘤相关骨髓纤维化以血细胞减少、骨髓纤维化、全身症状、髓外造血、脾大和生存期缩短为特征。Fedratinib是一种选择性口服JAK2抑制剂,最近在美国获批用于治疗中危-2或高危骨髓纤维化成人患者。在JAK抑制剂初治患者以及既往ruxolitinib治疗后复发、难治或不耐受的骨髓纤维化患者中,fedratinib显示出稳健的临床活性。
要点
- Fedratinib是一种选择性口服JAK2抑制剂,最近在美国获批用于中危-2或高危骨髓纤维化成人患者。
- Fedratinib对JAK抑制剂初治及既往ruxolitinib治疗后复发、难治或不耐受的骨髓纤维化患者均显示稳健临床活性。
- Fedratinib最常见不良事件为1-2级胃肠道事件,临床试验中约1%患者报告疑似Wernicke脑病。
核心结论
- Fedratinib最近获批为中危-2或高危骨髓纤维化成人患者提供了急需的治疗选择,补充了有限的治疗手段。
研究设计与样本
- 本文为综述,汇总fedratinib在小鼠模型和患者中的临床前与临床数据,并提及正在进行的III期试验评估长期安全性、疗效和总生存期。
主要发现
- 在JAK2V617F驱动的小鼠骨髓增殖性疾病模型中,fedratinib阻断STAT5磷酸化、提高生存率并改善骨髓纤维化相关疾病特征,包括降低白细胞计数、血细胞比容、脾大和纤维化。
- Fedratinib对含溴结构域蛋白4(BRD4)具有脱靶抑制活性;在骨髓增殖性肿瘤动物模型中,联合抑制JAK/STAT和BRD4协同阻断NF-kB过度活化和炎性细胞因子产生,减轻疾病负荷并逆转骨髓纤维化。
- 在患者中,fedratinib快速吸收,每日一次给药(有效半衰期41小时)。
- Fedratinib在JAK抑制剂初治患者以及既往ruxolitinib治疗后复发、难治或不耐受的骨髓纤维化患者中显示稳健临床活性;无论JAK2突变状态如何均有效。
- 脾脏和症状缓解通常在治疗最初1-2个月内出现;临床试验中因血液学不良事件停药不常见(约3%);fedratinib试验中约1%患者报告疑似Wernicke脑病病例。
关键数值与推荐
- Fedratinib最近在美国获批用于治疗中危-2或高危骨髓纤维化成人患者。
- Fedratinib有效半衰期为41小时,每日一次给药。
- 临床试验中因血液学不良事件停药约3%;疑似Wernicke脑病约1%。
- 应在fedratinib治疗前和治疗期间按医学指征监测硫胺素水平。
临床怎么用
- Fedratinib可用于JAK抑制剂初治以及既往ruxolitinib治疗后复发、难治或不耐受的骨髓纤维化患者,且无论JAK2突变状态如何均有效。
- 应在fedratinib治疗前和治疗期间按医学指征监测硫胺素水平。
局限性
- III期试验正在进行中,以评估fedratinib对长期安全性、疗效和总生存期的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) is characterized by cytopenias, marrow fibrosis, constitutional symptoms, extramedullary hematopoiesis, splenomegaly, and shortened survival. Constitutive activation of the janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway in MF leads to cell proliferation, inhibition of cell death, and clonal expansion of myeloproliferative malignant cells. Fedratinib is a selective oral JAK2 inhibitor recently approved in the United States for treatment of adult patients with intermediate-2 or high-risk MF. In mouse models of JAK2V617F-driven myeloproliferative disease, fedratinib blocked phosphorylation of STAT5, increased survival, and improved MF-associated disease features, including reduction of white blood cell counts, hematocrit, splenomegaly, and fibrosis. Fedratinib exerts off-target inhibitory activity against bromodomain-containing protein 4 (BRD4); combination JAK/STAT and BRD4 inhibition was shown to synergistically block NF-kB hyperactivation and inflammatory cytokine production, attenuating disease burden and reversing bone marrow fibrosis in animal models of MPNs. In patients, fedratinib is rapidly absorbed and dosed once daily (effective half-life 41 h). Fedratinib showed robust clinical activity in JAK-inhibitor-naïve patients and in patients with MF who were relapsed, refractory, or intolerant to prior ruxolitinib therapy. Fedratinib is effective regardless of JAK2 mutation status. Onset of spleen and symptom responses are typically seen within the first 1-2 months of treatment. The most common adverse events (AEs) with fedratinib are grades 1-2 gastrointestinal events, which are most frequent during early treatment and decrease over time. Treatment discontinuation due to hematologic AEs in clinical trials was uncommon (~3%). Suspected cases of Wernicke's encephalopathy were reported during fedratinib trials in ~1% of patients; thiamine levels should be monitored before and during fedratinib treatment as medically indicated. Phase III trials are ongoing to assess fedratinib effects on long-term safety, efficacy, and overall survival. The recent approval of fedratinib provides a much-needed addition to the limited therapeutic options available for patients with MF.
引用
- Talpaz M, Kiladjian JJ. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis. Leukemia. 2020. PMID: 32647323. doi:10.1038/s41375-020-0954-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。